According to reports, Covaxin shows 77.8 per cent efficacy in phase 3 trial data in review by Subject Expert Committee (SEC).
The Subject Expert Committee was to meet today to review the Phase III data of Covaxin.
The delay in submitting phase III data of the vaccine has led to questions being raised at various points of time.
Bharat Biotech’s Covaxin is one of the three vaccines which are currently being used in India. The phase III data of its vaccine have been questioned various times and that is what makes the data crucial which will ascertain the efficacy of the vaccine.
— Sumi Dutta (@SumiSukanya) June 22, 2021
The company has developed the vaccine in association with the Indian Council of Medical Research (ICMR).
(This is a developing story. More details awaited.)